Miller Fisher syndrome treated with plasmapheresis during pregnancy: Case report and review of the literature
DOI:
https://doi.org/10.18597/rcog.3611Abstract
Objective: To report the case of pregnant woman with Guillain-Barré syndrome (GBS) presenting as the Miller Fisher variant, and to review the literature on the diagnosis, treatment and prognosis of this GBS variant during gestation. Materials and Methods: Pregnant woman presenting at 27 weeks of gestation with Miller Fisher syndrome (MFS), treated in a military referral hospital with a satisfactory course after 15 days, continuation of normal pregnancy and delivery of a healthy neonate at 38 weeks. A search of the literature was conducted in the Medline via PubMed, Lilacs, SciELO, ScienceDirect and Ovid databases using the terms “Pregnancy,” “Miller Fisher syndrome,” “Guillain-Barré syndrome”. Cohorts, case series and case reports of pregnant women with MFS were included. Data on diagnostic methods, treatment and maternal and perinatal prognosis were extracted. The search was made on June 2020, with no restriction by date, but restriction by language (Spanish and English). Results: Overall, 423 titles were identified, three studies met the inclusion criteria, the three of them corresponding to case reports. All cases were found to be seropositive for anti-GQ1b ganglioside antibodies. No imaging abnormalities were found in any of the cases. Two patients received IV immunoglobulin and the third patient was kept under observation. No obstetric complications have be documented so far. Conclusion: There are few cases of MFS reported during pregnancy. Intravenous immunoglobulin is the most frequently used treatment option. Plasmapheresis was used in the case presented here. The impact of the Miller Fisher variant on the normal course of gestation and on long-term perinatal outcomes is unknown. Further studies that look into the diagnosis, treatment and prognosis of this condition are required.
References
Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet. 2005;366:1653-16. https://doi.org/10.1016/S0140-6736(05)67665-9
Malek E, Salameh J. Guillain-Barre Syndrome. Semin Neurol. 2019;39:589-95. https://doi.org/10.1055/s-0039-1693005
Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: A systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-33. https://doi.org/10.1159/000324710.
Donofrio P. Guillain-Barré Syndrome. Continuum. 2017;23(5):1295-1309. https://doi.org/10.1212/CON.0000000000000513.
Jung JH, Oh EH, Shin JH, Kim DS, Choi SY, Choi KD, Choi JH. Atypical clinical manifestations of Miller Fisher syndrome. Neurol Sci. 2019;40(1):67-73. https://doi.org/10.1007/s10072-018-3580-2.
Watrin L, Ghawche F, Larre P, et al. Guillain-Barre’syndrome (42 cases) occurring during a Zika virus outbreak in French Polynesia. Medicine (Baltimore). 2016;95(14):e3257. https://doi.org/10.1097/MD.0000000000003257
Willison H, Bart J, Doorn P. Guillain-Barré syndrome. Lancet. 2016; 338:717-27. https://doi.org/10.1016/S0140-6736(16)00339-1.
Patola M, Du Pasquier R, Schluep M, Regeniter A. Serum and CSF GQ1bantibodies in isolated ophthalmologic syndromes. Neurology. 2016;86:1780-4. https://doi.org/10.1212/WNL.0000000000002558
Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599-612. https://doi.org/10.1016/j.vaccine.2010.06.003.
Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinalfluid examination. J Neuroimmunol. 2004;148:200-5. https://doi.org/10.1016/j.jneuroim.2003.11.017
Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15:893-908. https://doi.org/10.1111/j.1468-1331.2008.02246.x
Verboon C, Dan Doorn P, Jacobs B. Treatment dilemmas in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2017;88(4):346-52. https://doi.org/10.1136/jnnp-2016-314862
Van den Berg B, Bunschoten C, van Doorn P, Jacobs B. Mortality in Guillain-Barre syndrome. Neurology. 2013;80(18):1650-4. https://doi.org/10.1212/WNL.0b013e3182904fcc
Cheng Q, Jiang GX, Fredrikson S, Link H, de Pedro-Cuesta J. Increased incidence of Guillain-Barré syndrome postpartum. Epidemiology. 1998;9:601-4. https://doi.org/10.1097/00001648-199811000-00006
Nelson LH, McLean WT Jr. Management of Landry-GuillainBarré syndrome in pregnancy. Obstet Gynecol. 1985;65(suppl):25S-29S.
Kasaven LS, Basu C. Guillain-Barré syndrome in pregnancy: Successful multidisciplinary approach. Eur J Obstet Gynecol Reprod Biol. 2018:228:332. https://doi.org/10.1016/j.ejogrb.2018.06.017.
Borchering RK, Huang AT, Mier-Y-Teran-Romero L, Rojas DP, Rodriguez-Barraquer I, Katzelnick LC, et al. Impacts of Zika emergence in Latin America on endemic dengue transmission. Nat Commun. 2019;10(1):1-9. https://doi.org/10.1038/s41467-019-13628-x
Mora-Salamanca AF, Porras-Ramírez A, Restrepo FPH. Burden of disease due to microcephaly associated with the Zika virus in Colombia. Cad Saude Publica. 2020;36(11):e00215319. https://doi.org/10.1590/0102-311X00215319
Ono M, Sato H, Shirahashi M, Tomioka N, Maeda J, Watanabe K, et al. Clinical Features of Miller-Fisher Syndrome in Pregnancy. Case Rep Obstet Gynecol. 2015;2015:1-3. https://doi.org/10.1155/2015/840680.
Munro Z, Fernandez D. Clinical Reasoning: Acute onset of diplopia in pregnancy. Neurology. 2018;91:e180-e184. https://doi.org/10.1212/WNL.0000000000005758.
Seo J, Kang M, Yoon B, Ji K, Oh S. Miller Fisher syndrome mimicking Wernicke encephalopathy during pregnancy. Ann Clin neurophysiol. 2019;21(1):53-56. https://doi.org/10.14253/acn.2019.21.1.53.
How to Cite
Downloads
Downloads
Published
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
